Europe Coagulation Analyzers Market

The Europe coagulation analyzers market is expected to grow from US$ 1,329.58 million in 2022 to US$ 1,850.01 million by 2028. It is estimated to grow at a CAGR of 5.7% from 2022 to 2028.

Rising Incidence of Cardiovascular Diseases Boosts Europe Coagulation Analyzers Market Growth

Cardiovascular diseases (CVDs) cause millions of deaths every year across the globe. The major causes of CVDs are hypertension, obesity, and diabetes. Further, CVDs majorly cause mortality and morbidity in Europe, accounting for 45% of deaths in the region and 37% in the European Union (EU) each year. High blood pressure is the major risk factor causing CVDs in low-and middle-income countries, resulting in more than 75% of death cases. In addition, a coagulation test can help prevent potential heart attack-causing blood clots. A coagulation analyzer is used during coronary artery bypass surgery and angioplasty to monitor information about blood clotting status. Thus, the increasing incidence of cardiovascular diseases is driving the growth of the Europe coagulation analyzers market.

Europe Coagulation Analyzers Market Overview

The Europe coagulation analyzers market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. Europe occupies a significant position in the global coagulation analyzers market and is estimated to register robust growth over the forecast period. The factors that are driving the growth of the market include the rising incidence of cardiovascular disorders, increasing availability of products, growing aging population, and rising awareness about coagulation analyzers.

Many people in Germany are suffering from cardiovascular disorders; the number is likely to increase with the growing number of older people in the country. In Germany, a heart attack is the most serious consequence of coronary heart disease (CHD). More than 3.6 million people suffer from CHD, and more than 1.3 million have survived a stroke. According to the latest WHO data published in 2020, in Germany, deaths caused due to coronary heart disease reached 147,055 or 20.98% of total deaths. Similarly, the prevalence of heart disease is high in the UK. As per the British Heart Foundation January 2021 report, ~7.6 million people suffer from heart and circulatory diseases in the UK. Heart and circulatory diseases cause more than 27% of all deaths in the UK. In addition, ~480 thousand diagnoses in 2019 were for ischemic heart disease. In 2019, the mortality rate from cardiovascular disease in the UK was 255 deaths per 100,000 population. Further, France is witnessing a rise in the geriatric population in recent years. According to The French Institute for Demographic Studies or INED, the aging population in France is expected to increase by 90% between 2030 and 2050. The aging population is prone to cardiac diseases and other abnormalities such as arrhythmia and myocardial infarction. According to the latest WHO data published in 2020, coronary heart disease deaths in Spain reached 51,684 or 15.64% of total deaths. Moreover, according to Statista, in 2020, Spain had a mortality rate from ischemic heart disease of ~55.59 deaths per 100,000 inhabitants. Thus, there is an increasing demand for diagnosing equipment in the hospitals across the region.

Europe Coagulation Analyzers Market Revenue and Forecast to 2028 (US$ Million)

Europe Coagulation Analyzers Strategic Insights

Strategic insights for the Europe Coagulation Analyzers provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Coagulation Analyzers Report Scope

Europe Coagulation Analyzers Regional Insights

The geographic scope of the Europe Coagulation Analyzers refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Europe Coagulation Analyzers Market Segmentation

The Europe coagulation analyzers market is segmented on the basis of product, test, technology, end users, and country.

Based on product, the Europe coagulation analyzers market is bifurcated intoclinical laboratory analyzers and point-of-care testing analyzers. The clinical laboratory analyzers segment held a larger Europe coagulation analyzers market share in 2022.

Based on test, the Europe coagulation analyzers market is segmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, D-dimer testing, platelet function tests, anti-factor XA tests, heparin and protamine dose response tests for act, and others. The prothrombin time testing segment held the largest Europe coagulation analyzers market share in 2022.

Based on technology, the Europe coagulation analyzers market is segmented into optical technology, mechanical technology, electrochemical technology, and other technologies. The optical technology segment held the largest Europe coagulation analyzers market share in 2022.

Based on end users, the Europe coagulation analyzers market is segmented into hospitals, clinical laboratories, point-of-care testing, and others. The clinical laboratories segment held the largest Europe coagulation analyzers market share in 2022.

Based on country, the Europe coagulation analyzers market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. Germany dominated the Europe coagulation analyzers market share in 2022.

Abbott Laboratories; Bio Group Medical System SRL; Danaher Corp; F. Hoffmann-La Roche Ltd; Horiba Ltd.; Nihon Kohden Corp; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Sysmex Corporation; and Thermo Fisher Scientific Inc are the leading companies operating in the Europe coagulation analyzers market.